drugset / Trial / NCT05950815
A Study of PM1015 in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
PM1015 is a specific antibody targeting CD73. This is a phase I study to evaluate the efficacy and safety of PM1015 in patients with advanced solid tumor.
Timeline
- Start
- 2022-05-10
- Primary completion
- 2023-09-30
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PM1015 | Protein / enzyme biologic | — | Intravenous |
| Background | Pemetrexed | Small molecule | — | — |
Indications
No indication recorded.